Compare Novo Nordisk A/S (NVO) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rocket Lab USA Inc — how do they compare? Novo Nordisk A/S trades at $45.02 (market cap $198.57B), while Rocket Lab USA Inc trades at $63.16 (market cap $40.33B). The key difference: Novo Nordisk A/S is far larger — about 4.9× Rocket Lab USA Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| NVO | RKLB | |
|---|---|---|
Market Cap | $198.57B | $40.33B |
Sector | Health | Technology |
52-Week High | $63.98 | $150.23 |
52-Week Low | $35.29 | $39.48 |
Enterprise Value | $213.37B | $38.16B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Rocket Lab (RKLB) trades at $65.87, down 56% from its 52-week high, with a bearish technical signal but strong analyst support. Q2 2026 revenue grew 62% year-over-year to $234 million, yet the company posted a net loss margin of -21.51%. Recent news highlights Neutron rocket delays to 2027 and a CFO stock sale, while Cathie Wood's ARK Invest added $45 million in shares (GuruFocus, September 7, 2026).
Outlook hinges on Neutron's successful deployment and profitability by 2028, offering high growth potential but facing execution risks and cash burn. Analysts see 78% upside to a $117.44 consensus target, though technical weakness and competitive pressures warrant caution for investors seeking space exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
